Search research articles
Contact Us
Filters
Showing results (11-20 of 38) with videos related to
Page
of 4
Sort By:
Nature Communications
|
January 27, 2011
An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cells
Hideaki Tsutsui, Bahram Valamehr, Antreas Hindoyan, et al.
Stem Cell Reports
|
March 28, 2014
Platform for induction and maintenance of transgene-free hiPSCs resembling ground state pluripotent stem cells
Bahram Valamehr, Megan Robinson, Ramzey Abujarour, et al.
Future Science OA
|
May 31, 2024
A chemical approach facilitates CRISPRa-only human iPSC generation and minimizes the number of targeted loci required
Ramzey Abujarour, Jason Dinella, Mochtar Pribadi, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 8, 2011
Suppression of leukemia development caused by PTEN loss
Wei Guo, Suzanne Schubbert, James Y Chen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
June 26, 2021
Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C<sup>+</sup> NK cells to target myeloid leukemia
Emily Chiu, Martin Felices, Frank Cichocki, et al.
Journal for Immunotherapy of Cancer
|
December 6, 2023
iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting
Kristin M Snyder, Kate J Dixon, Zachary Davis, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 16, 2008
Hydrophobic surfaces for enhanced differentiation of embryonic stem cell-derived embryoid bodies
Bahram Valamehr, Steven J Jonas, Julien Polleux, et al.
Blood
|
December 20, 2019
Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity
Huang Zhu, Robert H Blum, Ryan Bjordahl, et al.
Frontiers in Immunology
|
August 5, 2024
iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma
Kate J Dixon, Kristin M Snyder, Melissa Khaw, et al.
The Lancet. Haematology
|
July 3, 2025
Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study
Paolo Strati, Januario Castro, Aaron Goodman, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 38) with videos related to
Sort By:
Page
of 4
Nature Communications
|
January 27, 2011
An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cells
Hideaki Tsutsui, Bahram Valamehr, Antreas Hindoyan, et al.
Stem Cell Reports
|
March 28, 2014
Platform for induction and maintenance of transgene-free hiPSCs resembling ground state pluripotent stem cells
Bahram Valamehr, Megan Robinson, Ramzey Abujarour, et al.
Future Science OA
|
May 31, 2024
A chemical approach facilitates CRISPRa-only human iPSC generation and minimizes the number of targeted loci required
Ramzey Abujarour, Jason Dinella, Mochtar Pribadi, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 8, 2011
Suppression of leukemia development caused by PTEN loss
Wei Guo, Suzanne Schubbert, James Y Chen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
June 26, 2021
Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C<sup>+</sup> NK cells to target myeloid leukemia
Emily Chiu, Martin Felices, Frank Cichocki, et al.
Journal for Immunotherapy of Cancer
|
December 6, 2023
iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting
Kristin M Snyder, Kate J Dixon, Zachary Davis, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 16, 2008
Hydrophobic surfaces for enhanced differentiation of embryonic stem cell-derived embryoid bodies
Bahram Valamehr, Steven J Jonas, Julien Polleux, et al.
Blood
|
December 20, 2019
Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity
Huang Zhu, Robert H Blum, Ryan Bjordahl, et al.
Frontiers in Immunology
|
August 5, 2024
iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma
Kate J Dixon, Kristin M Snyder, Melissa Khaw, et al.
The Lancet. Haematology
|
July 3, 2025
Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study
Paolo Strati, Januario Castro, Aaron Goodman, et al.
Page
of 4